Table 11.6i

Immunosuppression Use for Antirejection Treatment from Transplant

to One Year Following Transplantation, 1996 to 2005

Recipients with Heart Transplants

  Year of Transplant
1996 1997 1998 1999 2000 2001 2002 2003 2004 2005
Transplants 2,343 2,293 2,348 2,188 2,199 2,202 2,155 2,057 2,015 2,125
Tx with Antirejection Treatments 854 871 979 916 901 849 803 657 534 532
Antibodies Any in Category 18.1% 19.3% 21.2% 17.7% 16.3% 15.5% 17.4% 18.4% 15.5% 18.2%
Atgam/NRATG/NRATS 5.4% 7.9% 7.3% 6.3% 4.6% 3.9% 4.0% 4.6% 2.6% 2.4%
OKT3 13.9% 13.1% 14.9% 7.4% 5.1% 5.8% 6.8% 4.1% 3.2% 3.4%
Thymoglobulin 0.0% 0.1% 0.2% 2.0% 3.8% 4.9% 6.4% 7.5% 8.6% 9.6%
Zenapax 0.0% 0.1% 0.8% 2.5% 3.0% 2.5% 1.5% 2.0% 1.5% 3.6%
Simulect 0.0% 0.0% 0.1% 0.9% 2.0% 0.4% 0.4% 1.4% 0.6% 0.8%
Campath 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.2% 0.2%
Corticosteroids Any in Category 88.3% 88.6% 87.9% 91.3% 92.3% 92.7% 92.2% 92.5% 91.4% 90.8%
Steroids 88.3% 88.6% 87.9% 91.3% 92.3% 92.7% 92.2% 92.5% 91.4% 90.8%
Antimetabolites Any in Category 5.4% 7.6% 6.5% 4.6% 4.4% 2.0% 3.0% 3.5% 1.7% 2.3%
Cytoxan 1.8% 3.6% 2.5% 2.1% 1.7% 0.5% 0.9% 1.7% 1.3% 1.3%
Methotrexate 3.6% 4.1% 4.3% 2.6% 2.8% 1.5% 2.1% 1.8% 0.4% 0.9%


Source: OPTN/SRTR Data as of May 1, 2007.

Individual drug percentages will not necessarily add up to the drug category percentages, as patients may be prescribed more than one drug within the same category.